These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 6300010)

  • 1. o,p'-DDD (mitotane) treatment of canine pituitary-dependent hyperadrenocorticism.
    Peterson ME
    J Am Vet Med Assoc; 1983 Mar; 182(5):527-8. PubMed ID: 6300010
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnosis and management of concurrent diabetes mellitus and hyperadrenocorticism in thirty dogs.
    Peterson ME; Nesbitt GH; Schaer M
    J Am Vet Med Assoc; 1981 Jan; 178(1):66-9. PubMed ID: 7009530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoadrenocorticism following therapy with o,p-DDD for hyperadrenocorticism in four dogs.
    Willard MD; Schall WD; Nachreiner RF; Shelton DG
    J Am Vet Med Assoc; 1982 Mar; 180(6):638-41. PubMed ID: 7068503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Laboratory parameters for the control of the course of therapy of canine Cushing's syndrome].
    Reusch C; Hähnle B
    Tierarztl Prax; 1991 Feb; 19(1):102-6. PubMed ID: 1646492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Problems associated with medical therapy of canine hyperadrenocorticism.
    Nichols R
    Probl Vet Med; 1990 Dec; 2(4):551-6. PubMed ID: 2134073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the urine cortisol-to-creatinine ratio for monitoring dogs with pituitary-dependent hyperadrenocorticism during induction treatment with mitotane (o,p'-DDD).
    Randolph JF; Toomey J; Center SA; Scarlett JM; Reimers T; Graham P; Nachreiner RF
    Am J Vet Res; 1998 Mar; 59(3):258-61. PubMed ID: 9522940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitotane (o,p'-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism.
    Kintzer PP; Peterson ME
    J Vet Intern Med; 1991; 5(3):182-90. PubMed ID: 1656032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical treatment of pituitary-dependent hyperadrenocorticism. Mitotane.
    Peterson ME; Kintzer PP
    Vet Clin North Am Small Anim Pract; 1997 Mar; 27(2):255-72. PubMed ID: 9076906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical treatment of pituitary-dependent hyperadrenocorticism in dogs.
    Peterson ME; Kintzer PP
    Semin Vet Med Surg Small Anim; 1994 Aug; 9(3):127-31. PubMed ID: 7938931
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of o,p'-DDD on plasma ACTH concentration in Cushing's disease.
    Bruno OD; Hoschoian JC; Andrada JA
    Medicina (B Aires); 1979; 39(2):229-34. PubMed ID: 228150
    [No Abstract]   [Full Text] [Related]  

  • 11. [Experiences with Lysodren treatment of Cushing's syndrome in dogs].
    Opitz M; Lettow E; Loppnow H; Grevel V
    Tierarztl Prax; 1983; 11(4):507-20. PubMed ID: 6658774
    [No Abstract]   [Full Text] [Related]  

  • 12. [Case presentation in small animal medicine].
    Gfeller G; Reusch C
    Schweiz Arch Tierheilkd; 1998; 140(9):375-9. PubMed ID: 9757786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitotane treatment of 32 dogs with cortisol-secreting adrenocortical neoplasms.
    Kintzer PP; Peterson ME
    J Am Vet Med Assoc; 1994 Jul; 205(1):54-61. PubMed ID: 7928549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diseases of the adrenal cortex of dogs and cats.
    Kaufman J
    Mod Vet Pract; 1984 Jun; 65(6):429-34. PubMed ID: 6330521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of non-selective adrenocorticolysis by o,p'-DDD in 129 dogs with pituitary-dependent hyperadrenocorticism.
    den Hertog E; Braakman JC; Teske E; Kooistra HS; Rijnberk A
    Vet Rec; 1999 Jan; 144(1):12-7. PubMed ID: 10028568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of urine cortisol:creatinine ratio versus adrenocorticotropic hormone stimulation testing for monitoring mitotane treatment of pituitary-dependent hyperadrenocorticism in dogs.
    Angles JM; Feldman EC; Nelson RW; Feldman MS
    J Am Vet Med Assoc; 1997 Oct; 211(8):1002-4. PubMed ID: 9343543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An alternative protocol for the medical management of canine pituitary-dependent hyperadrenocorticism.
    Rijnberk A; Belshaw BE
    Vet Rec; 1988 May; 122(20):486-8. PubMed ID: 3420770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experiences with Lysodren therapy of Cushing's syndrome in the dog (1)].
    Opitz M; Lettow E; Loppnow H; Grevel V
    Tierarztl Prax; 1983; 11(3):369-84. PubMed ID: 6636131
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs.
    Feldman EC; Nelson RW; Feldman MS; Farver TB
    J Am Vet Med Assoc; 1992 Jun; 200(11):1642-7. PubMed ID: 1320600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane.
    Reine NJ
    Clin Tech Small Anim Pract; 2007 Feb; 22(1):18-25. PubMed ID: 17542193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.